SAN FRANCISCO & LONDON--(BUSINESS WIRE)--Aiolos Bio, Inc., (“Aiolos” or “the Company) a clinical-stage biotechnology company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions, today announced the appointments of René van der Merwe, MBChB, as Chief Medical Officer, and Tapan Maniar, Ph.D.

旧金山和伦敦——（商业新闻短讯）——Aiolos Bio，Inc.（“Aiolos”或“该公司”）是一家临床阶段的生物技术公司，专注于解决呼吸道和炎症患者未满足的治疗需求，今天宣布任命MBChB的Renévan der Merwe为首席医疗官，Tapan Maniar博士。

as Chief Business Officer..

作为首席商务官。。

“We are delighted to welcome René and Tapan as key members of our leadership team at this exciting time for the Company as we prepare to initiate a Phase 2 clinical trial for our lead drug candidate, AIO-001, in moderate-to-severe asthma patients,” said Khurem Farooq, Co-Founder and Chief Executive Officer of Aiolos Bio.

Aiolos Bio联合创始人兼首席执行官Khurem Farooq说：“我们很高兴欢迎René和Tapan在这个激动人心的时刻成为我们领导团队的关键成员，因为我们准备为我们的主要候选药物AIO-001启动中重度哮喘患者的2期临床试验。”。

“René’s over 20 years of clinical development experience and deep respiratory expertise will be instrumental in supporting the advancement of our innovative lead therapy and furthering the Company’s mission of helping patients and their caregivers breathe easier. Likewise, Tapan’s strategic acumen and diverse skill set across business development, M&A, and capital formation will serve Aiolos well as we continue to build out our operations.”.

“René拥有20多年的临床开发经验和深呼吸专业知识，这将有助于推动我们创新的铅疗法的发展，并进一步推动公司帮助患者及其护理人员呼吸更加轻松的使命。同样，Tapan在业务开发、并购和资本形成方面的战略敏锐度和多样化技能将为Ai服务奥洛斯，以及我们继续建设我们的业务。”。

Dr. van der Merwe brings more than two decades of R&D experience to Aiolos Bio, having led global development programs for multiple approved asthma biologics. She served as Vice President of Respiratory Development at AstraZeneca’s biologics division, MedImmune, where she was Clinical Program lead for tezepelumab and benralizumab in asthma, COPD, and atopic dermatitis.

van der Merwe博士为Aiolos Bio带来了20多年的研发经验，他领导了多项经批准的哮喘生物制剂的全球开发计划。她曾担任阿斯利康生物制剂部门MedImmune的呼吸发育副总裁，在那里她是替塞单抗和贝那利单抗治疗哮喘，COPD和特应性皮炎的临床项目负责人。

Previously, Dr. van der Merwe held roles as Senior Vice President of Global Clinical Development at DBV Technologies and most recently served as Chief Medical Officer and Head of Clinical Development at Galvani Bioelectronics, a collaboration between GSK and Verily Lifesciences..

此前，van der Merwe博士曾担任DBV Technologies全球临床开发高级副总裁，最近担任葛兰素史克（GSK）与Verily Lifesciences合作的Galvani Bioelectronics首席医疗官兼临床开发负责人。。

“I’m thrilled to be joining the talented team at Aiolos Bio,” said Dr. Van der Merwe. “The opportunity to lead the development of this potentially best-in-class asset across multiple indications and bring real relief to patients and caregivers alike is truly exciting.” She added that one of the elements that attracted her to Aiolos was the mature state of the development program for AIO-001.

范德梅尔韦博士说：“我很高兴能加入Aiolos Bio的天才团队。”。“有机会在多个适应症中领导这一潜在的同类最佳资产的开发，并为患者和护理人员带来真正的缓解，这确实令人兴奋。”她补充说，吸引她加入Aiolos的因素之一是AIO-001开发计划的成熟状态。

“AIO-001 has been tested in healthy volunteers and moderate-to-severe asthmatics in multiple Phase 1 studies and it looks to be well tolerated, in addition to exhibiting an impressive pharmacokinetic (PK) and pharmacodynamic (PD) profile sustained through 24 weeks. We look forward to presenting and publishing data in 2024.” Dr.

“AIO-001已经在健康志愿者和中重度哮喘患者的多个1期研究中进行了测试，除了表现出令人印象深刻的药代动力学（PK）和药效学（PD）概况外，它看起来耐受性良好，持续24周。我们期待着在2024年提供和发布数据。”。

Van der Merwe will join Aiolos Bio effective January 2,2024..

范德梅尔维将于2014年1月2日加入Aiolos Bio。。

Dr. Maniar brings a wealth of leadership experience across business development, operations, and strategic planning. He joins Aiolos Bio from Bain Capital Life Sciences where he led and managed investments across therapeutic areas. Previously, Dr. Maniar served as Genentech’s head of business development for technology platforms, where he worked closely with senior leaders of the R&D and commercial teams.

Maniar博士在业务开发、运营和战略规划方面拥有丰富的领导经验。他加入了贝恩资本生命科学公司的Aiolos Bio，领导并管理了治疗领域的投资。此前，Maniar博士曾担任基因泰克技术平台业务开发主管，与研发和商业团队的高级领导密切合作。

Prior to Genentech, he was an Engagement Manager in McKinsey & Company’s healthcare practice, specializing on topics including portfolio strategy and business development. Dr. Maniar earned his Ph.D. in Neuroscience at The Rockefeller University..

在加入基因泰克（Genentech）之前，他是麦肯锡公司（McKinsey&Company）医疗保健业务的业务经理，专门研究投资组合战略和业务发展等主题。Maniar博士在洛克菲勒大学获得了神经科学博士学位。。

“I’m excited to join Khurem and the Aiolos team on this important mission and for the unique opportunity to help shape the early direction of the company and support the development of AIO-001,” said Dr. Maniar. “With the support of an exceptional investor syndicate we are well positioned to advance a best-in-class pipeline and are committed to delivering meaningful change for patients struggling with asthma and other immune disorders.”.

Maniar博士说：“我很高兴能加入Khurem和Aiolos团队，完成这项重要任务，并有机会帮助塑造公司的早期方向，支持AIO-001的发展。”。“在一个特殊的投资者财团的支持下，我们有能力推进一流的渠道，并致力于为患有哮喘和其他免疫疾病的患者提供有意义的改变。”。

Aiolos Bio launched in October 2023 with a $245 million Series A investment co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments with additional investment from RA Capital Management to advance AIO-001 into a Phase 2 clinical trial in moderate-to-severe asthma patients..

Aiolos Bio于2023年10月推出，由Atlas Venture，Bain Capital Life Sciences，Forbion和Sofinnova Investments共同领导，a系列投资2.45亿美元，RA Capital Management追加投资，将AIO-001推进中重度哮喘患者的2期临床试验。。

About AIO-001

关于AIO-001

The Company’s lead asset, AIO-001, is a monoclonal antibody that binds and blocks a clinically validated target protein known as thymic stromal lymphopoietin (TSLP). TSLP has a central role in driving inflammation, including in asthma. Inhibition of the TSLP ligand is the only biological approach that has demonstrated clinical benefit for moderate-to-severe asthma patients regardless of endotype.

该公司的主要资产AIO-001是一种单克隆抗体，可结合并阻断临床验证的靶蛋白胸腺基质淋巴细胞生成素（TSLP）。TSLP在驱动炎症（包括哮喘）中起着核心作用。抑制TSLP配体是唯一一种生物学方法，已证明对中度至重度哮喘患者具有临床益处，无论其内型如何。

AIO-001 is currently in development for moderate-to-severe asthma and it has the potential to be administered only twice per year attributed to its differentiated potency and long half-life..

AIO-001目前正在开发用于中度至重度哮喘，由于其不同的效力和较长的半衰期，它每年只能服用两次。。

AIO-001 was originally developed through early clinical stages by Jiangsu Hengrui Pharmaceuticals Co., Ltd, who retains commercialization rights to the greater China market.

AIO-001最初是由江苏恒瑞制药有限公司通过早期临床阶段开发的，该公司保留了大中华区市场的商业化权利。

About Aiolos Bio

关于Aiolos Bio

Aiolos Bio is committed to helping patients breathe easier as we look to reimagine treatment for patients with respiratory and inflammatory diseases. Our lead drug candidate is AIO-001, a humanized, anti-TSLP mAb in development for moderate-to-severe asthma. Our team has a long history of successful drug development in respiratory and immunological diseases – collectively amassing more than 30 FDA approvals – and seeks to leverage this expertise to meet.

Aiolos Bio致力于帮助患者呼吸更轻松，因为我们希望为呼吸和炎症疾病患者重新想象治疗方法。我们的主要候选药物是AIO-001，一种正在开发用于中重度哮喘的人源化抗TSLP单克隆抗体。我们的团队在呼吸系统疾病和免疫疾病的成功药物开发方面有着悠久的历史-总共获得了30多个FDA批准-并试图利用这些专业知识来满足。

the considerable unmet need that still exists for patients living with asthma around the world. For more information, please visit www.aiolosbio.com.

世界各地哮喘患者仍然存在大量未满足的需求。有关更多信息，请访问www.aiolosbio.com。